End-of-day quote
Bombay S.E.
06:00:00 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
18.91
INR
|
-4.97%
|
|
-3.40%
|
-24.57%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
55.62
|
80.28
|
158.4
|
498.6
|
2,655
|
10,937
|
Enterprise Value (EV)
1 |
45.59
|
74.67
|
255.3
|
484.2
|
2,437
|
11,499
|
P/E ratio
|
697
x
|
28.9
x
|
33
x
|
46.3
x
|
48.9
x
|
33.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
35
x
|
2.78
x
|
0.18
x
|
0.1
x
|
0.52
x
|
0.27
x
|
EV / Revenue
|
28.7
x
|
2.58
x
|
0.28
x
|
0.1
x
|
0.48
x
|
0.28
x
|
EV / EBITDA
|
-67.6
x
|
19.7
x
|
37.2
x
|
27.8
x
|
36.3
x
|
34.4
x
|
EV / FCF
|
-117
x
|
-15.3
x
|
-2.47
x
|
4.37
x
|
12.8
x
|
-12.5
x
|
FCF Yield
|
-0.85%
|
-6.54%
|
-40.5%
|
22.9%
|
7.82%
|
-8.02%
|
Price to Book
|
1.81
x
|
2.39
x
|
4.11
x
|
10.1
x
|
25.6
x
|
25.5
x
|
Nbr of stocks (in thousands)
|
403,200
|
403,200
|
403,200
|
403,200
|
403,200
|
403,200
|
Reference price
2 |
0.1379
|
0.1991
|
0.3929
|
1.237
|
6.586
|
27.12
|
Announcement Date
|
9/7/19
|
9/7/20
|
9/2/21
|
8/27/22
|
6/27/23
|
6/4/24
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
1.591
|
28.9
|
900.4
|
5,048
|
5,098
|
40,417
|
EBITDA
1 |
-0.674
|
3.8
|
6.854
|
17.4
|
67.16
|
334.5
|
EBIT
1 |
-0.688
|
3.75
|
6.616
|
17.02
|
65.65
|
334
|
Operating Margin
|
-43.24%
|
12.97%
|
0.73%
|
0.34%
|
1.29%
|
0.83%
|
Earnings before Tax (EBT)
1 |
0.192
|
3.749
|
6.528
|
15.25
|
73.96
|
504.5
|
Net income
1 |
0.08
|
2.77
|
4.805
|
10.78
|
54.26
|
327.3
|
Net margin
|
5.03%
|
9.58%
|
0.53%
|
0.21%
|
1.06%
|
0.81%
|
EPS
2 |
0.000198
|
0.006900
|
0.0119
|
0.0267
|
0.1346
|
0.8118
|
Free Cash Flow
1 |
-0.389
|
-4.886
|
-103.5
|
110.7
|
190.6
|
-922.2
|
FCF margin
|
-24.45%
|
-16.91%
|
-11.49%
|
2.19%
|
3.74%
|
-2.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
636.27%
|
283.79%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
1,027.02%
|
351.26%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/7/19
|
9/7/20
|
9/2/21
|
8/27/22
|
6/27/23
|
6/4/24
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
1 |
-
|
-
|
96.9
|
-
|
-
|
562
|
Net Cash position
1 |
10
|
5.61
|
-
|
14.4
|
219
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
14.14
x
|
-
|
-
|
1.679
x
|
Free Cash Flow
1 |
-0.39
|
-4.89
|
-103
|
111
|
191
|
-922
|
ROE (net income / shareholders' equity)
|
0.26%
|
8.62%
|
13.3%
|
24.5%
|
70.9%
|
123%
|
ROA (Net income/ Total Assets)
|
-1.29%
|
6.01%
|
1.93%
|
0.81%
|
0.6%
|
1.35%
|
Assets
1 |
-6.198
|
46.06
|
248.7
|
1,329
|
9,112
|
24,322
|
Book Value Per Share
2 |
0.0800
|
0.0800
|
0.1000
|
0.1200
|
0.2600
|
1.070
|
Cash Flow per Share
2 |
0.0300
|
0.0200
|
0.0200
|
0.0400
|
0.5400
|
0.0400
|
Capex
|
-
|
2.44
|
0.39
|
0.5
|
0.43
|
-
|
Capex / Sales
|
-
|
8.45%
|
0.04%
|
0.01%
|
0.01%
|
-
|
Announcement Date
|
9/7/19
|
9/7/20
|
9/2/21
|
8/27/22
|
6/27/23
|
6/4/24
|
|
1st Jan change
|
Capi.
|
---|
| -24.57% | 91.31M | | +59.97% | 840B | | +37.70% | 621B | | -6.18% | 354B | | +15.61% | 319B | | +8.44% | 297B | | +13.23% | 237B | | +14.32% | 221B | | +0.33% | 220B | | +9.68% | 169B |
Other Pharmaceuticals
|